​

Lakefront Biotherapeutics Stock (NASDAQ:LKFT)


RevenueFinancialsChartTranscripts

Previous Close

$29.38

52W Range

$25.68 - $37.78

50D Avg

$28.27

200D Avg

$30.19

Market Cap

$1.97B

Avg Vol (3M)

$251.23K

Beta

0.12

Div Yield

-

LKFT Company Profile


Lakefront Biotherapeutics NV, formerly Galapagos NV, is a biotechnology company that focuses on transforming patient outcomes through scientific innovation. It is dedicated to building a pipeline of medicines for patients with serious diseases in therapeutic areas of unmet need, prioritizing oncology and immunology & inflammation programs. The company's clinical-stage portfolio is anchored by potential first-in-class treatments for autoimmune diseases.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

BE

Employees

452

IPO Date

May 05, 2005

Website

LKFT Performance


LKFT Financial Summary


Dec 25
Revenue$1.11B
Operating Income$501.39M
Net Income$320.88M
EBITDA$358.96M
Basic EPS$4.87
Diluted EPS$4.87

Fiscal year ends in Dec 25 | Currency in EUR

Latest Earnings Call Transcripts


Q1 26May 07, 26 | 8:00 AM
Q4 25Feb 24, 26 | 8:00 AM
Q3 25Nov 06, 25 | 8:00 AM